Latest On MediPharm Labs Corp (MEDIF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-15 19:47 EST | News | MediPharm Labs GAAP EPS of -C$0.01, revenue of C$5.84M | N/A |  |
| 2023-05-15 19:46 EST | News | MediPharm Labs Corp. (MEDIF) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-04-13 15:50 EST | News | MediPharm to cut ~30% staff amid restructuring | N/A | |
| 2023-04-07 00:37 EST | News | Vivo Cannabis reports Q4 results | N/A | |
| 2022-12-23 03:14 EST | News | MediPharm Labs to acquire VIVO Cannabis in all-equity transaction | N/A | |
| 2022-11-14 21:12 EST | News | MediPharm Labs Corp. (MEDIF) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-08-16 03:08 EST | News | MediPharm Labs Corp. (MEDIF) CEO David Pidduck on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-07-11 13:51 EST | News | MediPharm Labs enters $6.2M for the sale of Australian facility | N/A | |
| 2022-05-17 02:09 EST | News | MediPharm Labs (MEDIF) CEO, David Pidduck on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-17 02:09 EST | News | MediPharm Q1 net loss narrows; expects top-line to improve in Q2 | N/A | |
| 2022-04-20 08:42 EST | News | David Pidduck is the new CEO of MediPharm Labs | N/A | |
| 2022-04-01 01:24 EST | News | MediPharm Labs reports Q4 results | N/A | |
| 2022-02-23 11:27 EST | News | MediPharm Labs files DMF with FDA for CBD manufacturing | N/A | |
| 2021-11-22 17:18 EST | News | MediPharm Labs: The Pharmaceutical Cannabis Play | N/A | |
| 2021-11-15 19:09 EST | News | MediPharm Labs Corp. (MEDIF) CEO Bryan Howcroft on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-31 21:39 EST | News | MediPharm Labs’ CBD50 candidate to advance in mid-stage trial for insomnia | N/A | |
| 2021-08-18 23:56 EST | News | MediPharm Labs gets export authorization to ship medical cannabis to Brazil | N/A | |
| 2021-08-17 07:23 EST | News | MediPharm Labs Corp. (MEDIF) CEO Keith Strachan on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-22 16:58 EST | News | Medipharm extends ADREXpharma partnership for cannabis in Germany | N/A | |
| 2021-07-22 16:57 EST | News | MediPharm Labs inks research agreement with McMaster University | N/A | |
| 2021-07-22 16:55 EST | News | MediPharm Labs receives Canadian GMP pharmaceutical drug establishment licence | N/A | |
| 2021-04-13 08:23 EST | News | Adjupharm inks supply agreement with Medipharm Labs | N/A | |
| 2021-04-06 15:09 EST | News | MediPharm Labs exports cannabis oil products first shipment to Germany | N/A | |
| 2021-04-01 10:29 EST | News | MediPharm Labs and STADA commence first sales in Germany under turnkey supply agreement | N/A | |
| 2021-03-31 14:59 EST | News | MediPharm Labs beats on revenue | N/A | |
| 2021-03-09 11:06 EST | News | MediPharm Labs ties up with Société Quebecois in Quebec supply deal | N/A | |
| 2021-03-08 16:10 EST | News | MediPharm Labs Australia signs supply and manufacturing agreement with Cannim | N/A | |
| 2021-03-03 01:23 EST | News | MediPharm ups size of capital raise to $29M | N/A | |
| 2021-03-02 06:45 EST | News | MediPharm Labs enters $20M bought deal equity financing | N/A | |
| 2021-02-24 20:29 EST | News | MediPharm: We Were Wrong | N/A | |
| 2021-02-24 02:39 EST | News | MediPharm Labs: Undiscovered Gem In The Cannabis Sector | N/A | |
| 2021-02-17 15:37 EST | News | MediPharm Labs wins Cannabis Drug Licence from Health Canada | N/A | |
| 2021-01-29 12:17 EST | News | New finance chief for MediPharm Labs | N/A | |
| 2020-12-04 06:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-19 08:26 EST | News | MediPharm Labs Corp. 2020 Q3 - Results - Earnings Call Presentation | N/A | |
| 2020-11-18 05:01 EST | News | MediPharm Labs reports Q3 results | N/A | |
| 2020-11-18 05:01 EST | News | MediPharm Labs (MEDIF) CEO, Pat McCutcheon on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-17 23:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-12 14:53 EST | News | MediPharm Labs CFO resigns | N/A | |
| 2020-10-22 14:04 EST | News | MediPharm Labs' Australia subsidiary inks deal with Sunco Green Pharma | N/A | |
| 2020-10-19 12:55 EST | News | MediPharm Labs commences clinical trial for use of cannabis to treat chronic kidney disease patients | N/A | |
| 2020-10-08 21:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-06 02:03 EST | News | MediPharm inks medical cannabis supply deal with STADA | N/A | |
| 2020-10-04 15:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-28 15:59 EST | News | MediPharm Labs takes 100% ownership in MediPharm Labs Australia | N/A | |
| 2020-09-26 16:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-25 09:43 EST | News | MediPharm Labs inks supply agreement with DanCann; forays into Denmark | N/A | |
| 2020-09-22 19:53 EST | News | MediPharm Labs inks distribution pact with XLR8 Brazil | N/A | |
| 2020-09-17 09:15 EST | Financials | Company financials have been released. | Neutral | |
About MediPharm Labs Corp (MEDIF):
MediPharm Labs Corp., together with its subsidiaries, produces and sells pharmaceutical-grade cannabis oil and concentrates for derivative products in Canada and Australia. It also provides cannabis contract processing services to licensed producers and growers; and tolling services to licensed cultivators in Canada. In addition, the company supplies purified cannabis concentrate raw materials and product formulations for ready-to-sell advanced cannabis products. Further, it engages in the real estate business. The company was founded in 2015 and is headquartered in Barrie, Canada.
General
- Name MediPharm Labs Corp
- Symbol MEDIF
- Type Common Stock
- Exchange OTCQX
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 230
- Fiscal Year EndDecember
- Web URLhttp://www.medipharmlabs.com
View More
Valuation
- Trailing PE 191.03
- Price/Sales (Trailing 12 Mt.) 1.16
- Price/Book (Most Recent Quarter) 1.22
- Enterprise Value Revenue 1.58
- Enterprise Value EBITDA 12.13
View More
Financials
- Most Recent Quarter 2020-09-30
- Profit Margin -62%
- Return on Assets -17%
- Return on Equity -34%
- Revenue Per Share $0
- Gross Profit 42.91 million
- Quarterly Earnings Growth -88.6%
View More
Highlights
- Market Capitalization 99.75 million
View More
Share Statistics
- Shares Outstanding 257.95 million
- Shares Float 139.98 million
- % Held by Insiders 1442%
- % Held by Institutions 14.96%
View More
Technicals
- Beta 0.81
- 52 Week High $1.7
- 52 Week Low $0.35
- 50 Day Moving Average 0.52
- 200 Day Moving Average 0.53
View More
Dividends
- Dividend Date 2018-10-04
- ExDividend Date N/A
- Dividend Yield 0%
View More
MediPharm Labs Corp (MEDIF) Dividend Calendar:
MEDIF's last dividend payment was made to shareholders on October 4, 2018.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
MediPharm Labs Corp (MEDIF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-16 | $N/A | -$0.11 | -$0.03 | -266.67% |
| 2020-06-30 | 2020-09-30 | $N/A | -$0.08 | -$0.04 | -106.5% |
| 2020-03-31 | 2020-06-30 | $N/A | -$0.01 | -$0.01 | -47% |
| 2019-12-31 | 2020-03-31 | $32.44 million | -$0.09 | $0.01 | -1024% |
| 2019-09-30 | 2019-12-31 | $43.39 million | -$0.02 | $0.03 | -169.33% |
| 2019-06-30 | 2019-09-30 | $31.47 million | $0.02 | $0.01 | 51% |
| 2019-03-31 | 2019-06-30 | $21.95 million | $0.01 | -$0.01 | 176% |
| 2018-12-31 | 2019-03-31 | $10.2 million | $-0.00 | ||
| 2018-09-30 | 2018-12-31 | $N/A | -$0.03 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $N/A | -$0.02 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $N/A | -$0.02 | $0.00 | |
| 2017-12-31 | 2018-03-31 | -$0.02 | $0.00 | ||
| 2017-09-30 | 2017-12-31 | -$0.01 | $0.00 | ||
| 2017-06-30 | 2017-09-30 | -$0.01 | $0.00 | ||
| 2017-03-31 | 2017-06-30 | -$0.01 | $0.00 | ||
| 2016-12-31 | 2017-03-31 | -$0.03 | $0.00 |
MediPharm Labs Corp (MEDIF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | 447000 | 420000 |
| Income Before Tax | N/A | N/A | N/A | -2.4 million | 5.4 million |
| Selling General Administrative | N/A | N/A | N/A | 11.89 million | 8.47 million |
| Gross Profit | N/A | N/A | N/A | 9.99 million | 14.75 million |
| Ebit | N/A | N/A | N/A | -1.51 million | 6.13 million |
| Operating Income | N/A | N/A | N/A | -2.5 million | 5.37 million |
| Income Tax Expense | -114000 | -285000 | -4.67 million | 1.14 million | 2.12 million |
| Total Revenue | N/A | N/A | N/A | 32.44 million | 43.39 million |
| Cost of Revenue | N/A | N/A | N/A | 22.46 million | 28.63 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 30000 |
| Net Income From Continuing Operations | N/A | N/A | N/A | -3.54 million | 3.28 million |
| Net Income Applicable to Common Shares | -14.96 million | -3.35 million | -17.09 million | -3.22 million | 3.38 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | -9.46 million | -10.8 million |
| Change to Liabilities | -5.46 million | -1.22 million | -6.76 million | -20.02 million | -3.95 million |
| Total Cash Flow from Investing Activities | -1 million | -2.92 million | -3.49 million | -9.46 million | -10.8 million |
| Net Borrowings | 17.22 million | 13.91 million | -341000 | 3.55 million | -46000 |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | 4.97 million | 218000 |
| Change to Operating Activities | -2.46 million | 735000 | 332000 | -2.62 million | 4.2 million |
| Change in Cash | N/A | N/A | N/A | -3.49 million | -30.61 million |
| Total Cash from Operating Activities | -9.38 million | -5.68 million | -15.39 million | 1.05 million | -20.12 million |
| Depreciation | N/A | N/A | N/A | 771000 | 539000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | 2.6 million | -11.66 million |
| Change to Account Receivables | N/A | N/A | N/A | N/A | -15.43 million |
| Other Cash Flow from Financing Activities | -72000 | -215000 | -76000 | 81000 | -164000 |
| Change to Net Income | 6.8 million | 524000 | 10.84 million | 8.73 million | 2.8 million |
| Capital Expenditures | N/A | N/A | N/A | 9.46 million | 10.8 million |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | 37.6 million | 54.05 million |
| Total Stockholder Equity | N/A | N/A | N/A | 131.55 million | 128.98 million |
| Other Current Liabilities | N/A | N/A | N/A | N/A | 716000 |
| Total Assets | N/A | N/A | N/A | 168.83 million | 183.02 million |
| Common Stock | 127.62 million | 125.52 million | 124.17 million | 122.81 million | 121.06 million |
| Other Current Assets | 3.05 million | N/A | N/A | N/A | 287000 |
| Retained Earnings | -43.59 million | -28.63 million | -25.28 million | -8.19 million | -4.97 million |
| Other Liabilities | 7.66 million | 6.93 million | N/A | N/A | N/A |
| Other Assets | 4.22 million | 5.37 million | 6.27 million | 6.71 million | 7.06 million |
| Cash | N/A | N/A | N/A | 38.63 million | 42.12 million |
| Total Current Liabilities | 14.66 million | N/A | N/A | 28.85 million | 53.56 million |
| Other Stockholder Equity | 21.36 million | 21.1 million | 19.78 million | 16.93 million | 12.89 million |
| Property, Plant & Equipment | 44.81 million | 45.55 million | 43.96 million | 42.23 million | 34.92 million |
| Total Current Assets | 101.01 million | N/A | N/A | 119.7 million | 140.85 million |
| Long Term Investments | N/A | N/A | N/A | 189000 | 189000 |
| Net Tangible Assets | 105.39 million | 117.98 million | 118.67 million | 131.55 million | 128.98 million |
| Short Term Investments | N/A | N/A | N/A | N/A | 200000 |
| Long Term Debt | N/A | N/A | N/A | 8.12 million | N/A |
| Inventory | 31.68 million | N/A | N/A | 51.49 million | 54.09 million |
| Accounts Payable | 5.97 million | N/A | N/A | 19.06 million | 41.64 million |
MediPharm Labs Corp (MEDIF) Chart:
MediPharm Labs Corp (MEDIF) News:
Below you will find a list of latest news for MediPharm Labs Corp (MEDIF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
MediPharm Labs Corp (MEDIF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
MediPharm Labs Corp (MEDIF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|